212 related articles for article (PubMed ID: 37473877)
1. Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children.
Zapata-Cobo P; Salvador-Martín S; Velasco M; Palomino LM; Clemente S; Segarra O; Moreno-Álvarez A; Fernández-Lorenzo A; Pérez-Moneo B; Montraveta M; Sánchez C; Tolín M; Loverdos I; Fobelo MJ; Navas-López VM; Magallares L; García-Romero R; Sánchez-Hernández JG; Rodríguez A; Bossacoma F; Balboa MJ; Salcedo E; Sanjurjo-Sáez M; López-Fernández LA
Pharmacol Res; 2023 Aug; 194():106859. PubMed ID: 37473877
[TBL] [Abstract][Full Text] [Related]
2. Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort.
Salvador-Martín S; Zapata-Cobo P; Velasco M; Palomino LM; Clemente S; Segarra O; Sánchez C; Tolín M; Moreno-Álvarez A; Fernández-Lorenzo A; Pérez-Moneo B; Loverdos I; Navas López VM; Millán A; Magallares L; Torres-Peral R; García-Romero R; Pujol-Muncunill G; Merino-Bohorquez V; Rodríguez A; Salcedo E; López-Cauce B; Marín-Jiménez I; Menchén L; Laserna-Mendieta E; Lucendo AJ; Sanjurjo-Sáez M; López-Fernández LA
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675312
[TBL] [Abstract][Full Text] [Related]
3. Genetic Predictors of Long-term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease.
Salvador-Martín S; Bossacoma F; Pujol-Muncunill G; Navas-López VM; Gallego-Fernández C; Viada J; Muñoz-Codoceo R; Magallares L; Martínez-Ojinaga E; Moreno-Álvarez A; Solar-Boga A; Segarra O; Clemente S; Rodriguez-Martinez A; Alvarez-Vayo C; Loverdos I; Merino-Bohórquez V; Balboa-Vega MJ; Blanca-García JA; Fobelo MJ; Millán-Jiménez A; García-Romero R; Sanchez C; Tolín M; Caldas RG; Eizaguirre FJ; Sánchez-Hernandez JG; Torres-Peral R; Aznal E; García-González X; Sanjurjo-Sáez M; López-Fernández LA
J Pediatr Gastroenterol Nutr; 2020 Oct; 71(4):508-515. PubMed ID: 32773718
[TBL] [Abstract][Full Text] [Related]
4. Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.
Salvador-Martín S; Raposo-Gutiérrez I; Navas-López VM; Gallego-Fernández C; Moreno-Álvarez A; Solar-Boga A; Muñoz-Codoceo R; Magallares L; Martínez-Ojinaga E; Fobelo MJ; Millán-Jiménez A; Rodriguez-Martinez A; Vayo CA; Sánchez C; Tolin M; Bossacoma F; Pujol-Muncunill G; González de Caldas R; Loverdos I; Blanca-García JA; Segarra O; Eizaguirre FJ; García-Romero R; Merino-Bohórquez V; Sanjurjo-Sáez M; López-Fernández LA
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397546
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of trough serum anti-TNF levels in paediatric inflammatory bowel disease.
Salvador-Martín S; Pujol-Muncunill G; Bossacoma F; Navas-López VM; Gallego-Fernández C; Segarra O; Clemente S; Muñoz-Codoceo R; Viada J; Magallares L; Martínez-Ojinaga E; Moreno-Álvarez A; Solar-Boga A; Loverdos I; Merino-Bohórquez V; Balboa-Vega MJ; Rodriguez-Martinez A; Alvarez-Vayo C; Sanchez C; Tolin M; Blanca-García JA; García-Romero R; Eizaguirre FJ; Sánchez-Hernandez JG; de Caldas RG; Millán-Jimenez A; Aznal E; Abarca-Zabalía J; Sanjurjo-Sáez M; López-Fernández LA
Br J Clin Pharmacol; 2021 Feb; 87(2):447-457. PubMed ID: 32478906
[TBL] [Abstract][Full Text] [Related]
6. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
7. Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment.
Salvador-Martín S; Rubbini G; Vellosillo P; Zapata-Cobo P; Velasco M; Palomino LM; Clemente S; Segarra O; Moreno-Álvarez A; Fernández-Lorenzo A; Pérez-Moneo B; Montraveta M; Sánchez C; Tolín M; Loverdos I; Fobelo MJ; Navas-López VM; Magallares L; García-Romero R; Torres-Peral R; Rodríguez A; Bossacoma F; Merino-Bohórquez V; Salcedo E; Álvarez R; Dopazo A; Sanjurjo-Sáez M; López-Fernández LA
Biomed Pharmacother; 2024 Apr; 173():116299. PubMed ID: 38401525
[TBL] [Abstract][Full Text] [Related]
8. Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease.
Prieto-Pérez R; Almoguera B; Cabaleiro T; Hakonarson H; Abad-Santos F
Int J Mol Sci; 2016 Feb; 17(2):225. PubMed ID: 26861312
[TBL] [Abstract][Full Text] [Related]
9. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
[TBL] [Abstract][Full Text] [Related]
10. Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy.
Miler M; Nikolac Gabaj N; Ćelap I; Grazio S; Tomašić V; Bišćanin A; Mitrović J; Đerek L; Morović-Vergles J; Vrkić N; Štefanović M
Rheumatol Int; 2021 Dec; 41(12):2195-2203. PubMed ID: 34623480
[TBL] [Abstract][Full Text] [Related]
11. Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab.
Bertani L; Barberio B; Fornili M; Antonioli L; Zanzi F; Casadei C; Benvenuti L; Facchin S; D'Antongiovanni V; Lorenzon G; Ceccarelli L; Baglietto L; de Bortoli N; Bellini M; Costa F; Savarino EV; Fornai M
Dig Liver Dis; 2022 Oct; 54(10):1367-1373. PubMed ID: 35393259
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease.
Bank S; Julsgaard M; Abed OK; Burisch J; Broder Brodersen J; Pedersen NK; Gouliaev A; Ajan R; Nytoft Rasmussen D; Honore Grauslund C; Roug S; Galsgaard J; Sprogøe Høyer Finsen D; Lindby K; ; Sørensen J; Larsen L; Rohr Andersen M; Brandslund I; Thomassen M; Green A; Bo Bojesen A; Bek Sørensen S; Vogel U; Andersen V
Aliment Pharmacol Ther; 2019 Apr; 49(7):890-903. PubMed ID: 30811631
[TBL] [Abstract][Full Text] [Related]
13. One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective study.
Cheli S; Savino D; De Silvestri A; Norsa L; Sansotta N; Penagini F; Dilillo D; Panceri R; Cattaneo D; Clementi E; Zuin G
Pharmacogenomics J; 2023 Sep; 23(5):112-118. PubMed ID: 37016150
[TBL] [Abstract][Full Text] [Related]
14. High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists.
Guo A; Ross C; Chande N; Gregor J; Ponich T; Khanna R; Sey M; Beaton M; Yan B; Kim RB; Wilson A
Sci Rep; 2022 Jan; 12(1):1185. PubMed ID: 35075155
[TBL] [Abstract][Full Text] [Related]
15. Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?
Gisbert JP; Chaparro M
Scand J Gastroenterol; 2015 Apr; 50(4):379-86. PubMed ID: 25636030
[TBL] [Abstract][Full Text] [Related]
16. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy.
Nigam GB; Bhandare AP; Antoniou GA; Limdi JK
Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):346-357. PubMed ID: 32889976
[TBL] [Abstract][Full Text] [Related]
17. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
[TBL] [Abstract][Full Text] [Related]
18. Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease.
Samuels A; Whaley KG; Minar P
Curr Gastroenterol Rep; 2023 Nov; 25(11):323-332. PubMed ID: 37695555
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP; Chaparro M
J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
[TBL] [Abstract][Full Text] [Related]
20. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
